Latest Myocardial infarction Stories

Acute cardiac care experts meeting at Acute Cardiac Care 2012 in Istanbul say that patients with severe chest pain should call the emergency number immediately as pre hospital care is essential to survival Experts in emergency cardiac care from around the world met in Istanbul to discuss ways to improve outcomes in patients with acute cardiac disease. This was the first annual meeting of the newly launched Acute Cardiovascular Care Association (ACCA) of the European Society of Cardiology...

Heart failure once severely shortened lives. Today, proper use of medications and devices can boost the pumping power of a failing heart and help people with heart failure enjoy a good quality of life for many years. Boston MA (PRWEB) October 11, 2012 People with heart failure once faced severely shortened lives. Today, proper use of medications and devices can boost the pumping power of a failing heart and help people with heart failure enjoy a good quality of life for many years,...

IRVINE, Calif., Oct. 11, 2012 /PRNewswire/ -- Aviir Inc., a biotechnology company dedicated to the prevention of cardiovascular disease through innovative laboratory tests, is featured in a new segment on PBS' American Health Journal. The American Health Journal is dedicated to educating the public on health care issues by providing information on the latest medical treatments and discoveries, highlighting companies that are making significant strides in medical and scientific...

With the results of a magnetic resonance imaging (MRI) study from the National Institutes of Health (NIH), researchers say they are closer to finding an imaging technique that can identify thickening of the coronary artery wall, an early stage of coronary heart disease (CAD). The study is published online in the journal Radiology. "Imaging the coronary arteries that supply the heart with blood is extremely difficult because they are very small and constantly in motion," said lead...

IRVINE, Calif., Oct. 9, 2012 /PRNewswire/ -- AtheroNova Inc. (OTCBB: AHRO) ("AtheroNova"), a biotech company focused on the research and development of compounds to regress atherosclerotic plaque announced today that the Company is supporting an additional preclinical study to expand the uses of compounds under the company's pending patents. The study is being conducted at UCLA's The David Geffen School of Medicine on a contract basis. "We are pleased to commence this significant...

Inflammation has a role in heart disease and may also be implicated in aging brain Daily low dose aspirin could slow the decline in brain power among elderly women at high risk of heart disease, indicates observational research published in the online journal BMJ Open. The researchers base their findings on 681 women between the ages of 70 and 92, 601 of whom were at high risk of heart disease and stroke, defined as a 10% or greater risk on a validated risk scale (Framingham). All...

Lee Rannals for redOrbit.com – Your Universe Online According to a study published in the journal JAMA, the use of beta-blockers was not associated with a lower risk of cardiovascular events. Scientists conducted the study to evaluate the association between beta-blocker use and long-term cardiovascular outcomes. The study included data form patients in the REduction of Atherothrombosis for Continued Health (REACH) registry. This registry included 44,708 patients who met the...

LAGUNA HILLS, Calif., Oct. 1, 2012 /PRNewswire/ -- LoneStar Heart Inc., based here, today announced the first patient was treated in the company's international multi-center AUGMENT-HF clinical trial of Algisyl-LVR at IRCCS San Raffaele Pisana and at Umberto I Policlinico, both located in Rome, Italy. The AUGMENT-HF clinical study follows on the success of a pilot study at the German Heart Center in Munich and Heart Center Dresden that established the safety and feasibility of...

IVUS data will evaluate plaque regression in patients with Coronary Artery Disease TSX Exchange Symbol: RVX CALGARY, Sept. 26, 2012 /PRNewswire/ - Resverlogix Corp. (TSX:RVX) today announced that it has completed enrollment in ASSURE, a Phase 2b clinical trial targeting high-risk cardiovascular disease patients. ASSURE will evaluate the ability of RVX-208, Resverlogix's BET protein inhibitor, to regress atherosclerotic disease versus placebo using intravascular ultrasound...

Striking findings highlight need for aggressive monitoring, early treatment to prevent later heart attacks, strokes A federally funded study led by researchers at Johns Hopkins Children's Center has found that children with mild to moderate kidney disease have abnormally thick neck arteries, a condition known as carotid atherosclerosis, usually seen in older adults with a long history of elevated cholesterol and untreated hypertension. The findings — published online ahead of print on...